Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $499.75 | 8 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| UROGEN PHARMA, INC. | $145.62 | 1 | $0 (2024) |
| GENZYME CORPORATION | $123.29 | 1 | $0 (2017) |
| Boston Scientific Corporation | $118.36 | 1 | $0 (2024) |
| Astellas Pharma US Inc | $53.77 | 1 | $0 (2019) |
| Ferring Pharmaceuticals Inc. | $15.69 | 1 | $0 (2024) |
| Philips Electronics North America Corporation | $14.58 | 1 | $0 (2021) |
| Tactile Systems Technology Inc | $14.43 | 1 | $0 (2021) |
| Bayer HealthCare Pharmaceuticals Inc. | $14.01 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $279.67 | 3 | UROGEN PHARMA, INC. ($145.62) |
| 2021 | $29.01 | 2 | Philips Electronics North America Corporation ($14.58) |
| 2019 | $53.77 | 1 | Astellas Pharma US Inc ($53.77) |
| 2017 | $137.30 | 2 | GENZYME CORPORATION ($123.29) |
All Payment Transactions
8 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | Boston Scientific Corporation | SpaceOAR System (Device) | Food and Beverage | In-kind items and services | $118.36 | General |
| Category: Space OAR_URO | ||||||
| 04/30/2024 | Ferring Pharmaceuticals Inc. | ADSTILADRIN (Biological) | Food and Beverage | In-kind items and services | $15.69 | General |
| Category: ONCOLOGY | ||||||
| 02/21/2024 | UROGEN PHARMA, INC. | JELMYTO (Drug) | Food and Beverage | In-kind items and services | $145.62 | General |
| Category: UROTHELIAL CANCER | ||||||
| 10/29/2021 | Philips Electronics North America Corporation | (6536) Phoenix (Device) | Food and Beverage | Cash or cash equivalent | $14.58 | General |
| Category: Medical Device | ||||||
| 10/29/2021 | Tactile Systems Technology Inc | Flexitouch Plus (Device), entre | Food and Beverage | In-kind items and services | $14.43 | General |
| Category: PNEUMATIC COMPRESSOR | ||||||
| 01/25/2019 | Astellas Pharma US Inc | — | Food and Beverage | In-kind items and services | $53.77 | General |
| 05/17/2017 | GENZYME CORPORATION | JEVTANA (Drug) | Food and Beverage | In-kind items and services | $123.29 | General |
| Category: ONCOLOGY | ||||||
| 03/01/2017 | Bayer HealthCare Pharmaceuticals Inc. | Xofigo (Drug) | Food and Beverage | In-kind items and services | $14.01 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 504 | 913 | $106,711 | $39,874 |
| 2022 | 8 | 557 | 1,023 | $76,833 | $47,634 |
| 2021 | 14 | 756 | 1,300 | $101,441 | $66,715 |
| 2020 | 10 | 594 | 964 | $77,662 | $45,819 |
All Medicare Procedures & Services
40 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 191 | 398 | $62,184 | $25,893 | 41.6% |
| 52000 | Diagnostic exam of bladder and urethra using an endoscope | Office | 2023 | 16 | 17 | $6,248 | $3,251 | 52.0% |
| 53661 | Subsequent dilation of urethra in female | Office | 2023 | 16 | 50 | $6,154 | $2,997 | 48.7% |
| 52332 | Insertion of stent in ureter using an endoscope | Facility | 2023 | 19 | 19 | $20,848 | $2,868 | 13.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 27 | 27 | $3,766 | $2,286 | 60.7% |
| 81000 | Manual urinalysis test with examination using microscope, non-automated | Office | 2023 | 192 | 353 | $2,033 | $1,383 | 68.0% |
| 76775 | Limited ultrasound scan behind abdominal cavity | Office | 2023 | 20 | 20 | $1,854 | $953.61 | 51.4% |
| 51798 | Ultrasound measurement of bladder capacity after voiding | Office | 2023 | 23 | 29 | $3,625 | $242.35 | 6.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 216 | 463 | $48,952 | $31,185 | 63.7% |
| 52000 | Diagnostic exam of bladder and urethra using an endoscope | Office | 2022 | 19 | 21 | $6,170 | $4,637 | 75.2% |
| 52332 | Insertion of stent in ureter using an endoscope | Facility | 2022 | 17 | 18 | $9,310 | $3,384 | 36.3% |
| 53661 | Subsequent dilation of urethra in female | Office | 2022 | 17 | 54 | $4,931 | $3,206 | 65.0% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 26 | 26 | $3,309 | $2,245 | 67.9% |
| 81000 | Manual urinalysis test with examination using microscope, non-automated | Office | 2022 | 220 | 395 | $1,723 | $1,537 | 89.2% |
| 76775 | Limited ultrasound scan behind abdominal cavity | Office | 2022 | 26 | 28 | $2,096 | $1,277 | 60.9% |
| 51798 | Ultrasound measurement of bladder capacity after voiding | Office | 2022 | 16 | 18 | $342.26 | $163.37 | 47.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 220 | 465 | $48,862 | $35,306 | 72.3% |
| 52000 | Diagnostic examination of the bladder and bladder canal (urethra) using an endoscope | Office | 2021 | 28 | 32 | $9,392 | $7,016 | 74.7% |
| 52332 | Insertion of stent in urinary duct (ureter) using an endoscope | Facility | 2021 | 22 | 23 | $9,442 | $4,371 | 46.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 53 | 61 | $8,985 | $3,991 | 44.4% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 38 | 38 | $4,820 | $3,664 | 76.0% |
| 53661 | Dilation of bladder canal (urethra), female, subsequent | Office | 2021 | 17 | 45 | $4,338 | $2,982 | 68.7% |
| 55700 | Biopsy of prostate gland | Office | 2021 | 12 | 12 | $4,562 | $2,568 | 56.3% |
| 76775 | Ultrasound behind abdominal cavity, limited | Office | 2021 | 39 | 43 | $3,986 | $2,121 | 53.2% |
| 81000 | Manual urinalysis test with examination using microscope, non-automated | Office | 2021 | 240 | 461 | $2,214 | $1,841 | 83.2% |
About Dr. Thomas Gianis, M.D
Dr. Thomas Gianis, M.D is a Urology healthcare provider based in Summit, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/16/2006. The National Provider Identifier (NPI) number assigned to this provider is 1376587501.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Thomas Gianis, M.D has received a total of $499.75 in payments from pharmaceutical and medical device companies, with $279.67 received in 2024. These payments were reported across 8 transactions from 8 companies. The most common payment nature is "Food and Beverage" ($499.75).
As a Medicare-enrolled provider, Gianis has provided services to 2,411 Medicare beneficiaries, totaling 4,200 services with total Medicare billing of $200,042. Data is available for 4 years (2020–2023), covering 40 distinct procedure/service records.
Practice Information
- Specialty Urology
- Location Summit, NJ
- Active Since 06/16/2006
- Last Updated 01/07/2024
- Taxonomy Code 208800000X
- Entity Type Individual
- NPI Number 1376587501
Products in Payments
- JELMYTO (Drug) $145.62
- JEVTANA (Drug) $123.29
- SpaceOAR System (Device) $118.36
- ADSTILADRIN (Biological) $15.69
- (6536) Phoenix (Device) $14.58
- Flexitouch Plus (Device) $14.43
- Xofigo (Drug) $14.01
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Urology Doctors in Summit
Alexander Haberman, Do, DO
Urology — Payments: $2,596
Joseph Caputo, M.d, M.D
Urology — Payments: $770.05
Vikas Bhatt, M.d, M.D
Urology — Payments: $281.05
Mr. Aaron Sulman, Md, MD
Urology — Payments: $218.24
Dr. Faizanahmed Munshi, Md, MD
Urology — Payments: $33.76